search
Back to results

Inhalation Flow Rate-study

Primary Purpose

Bronchiectasis

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
T-326 Inhaler
Sponsored by
Bayer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bronchiectasis focused on measuring Device study, Peak inspiratory flow rate, Non-cystic fibrosis bronchiectasis, T-326 Inhaler

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT)
  • Ability to reproducibly perform spirometry according to American Thoracic Society/European Respiratory Society criteria
  • Clinically stable in the opinion of the investigator at the time of the study visit.
  • Male and female patients ≥ 18 years of age.

Exclusion Criteria:

  • Pulmonary exacerbation (as judged by the investigator, based on the clinical condition of the subject and taking into account e.g., febrile infection of the lung, relevant decrease in Forced expiratory volume in the first second (FEV1) value, increased sputum production, sputum purulence, recent hospitalization) at study visit or within the preceding six (6) weeks.
  • History of lung transplant.
  • Recent significant hemoptysis (≥ 300 mL or requiring blood transfusion) in the preceding six (6) weeks before screening.
  • Established diagnosis of bronchial asthma.
  • Established diagnosis of cystic fibrosis.
  • Proof of any relevant medical finding or disease in the last three (3) months which might interfere with participation in the study or patient safety (e.g. pneumothorax, uncontrolled hypertension, uncontrolled cardiac arrhythmia, myocardial infarction, cerebral vascular accident).
  • A relevant disease that is considered to interfere with the study results is any disease that, except for the impairment of lung function, interferes with the patient's ability to inhale from the device. For example, COPD per se is usually not considered as a reason for patient exclusion, unless coughing or obliteration of the upper airways with sputum interferes with the patient's ability to inhale from the device.
  • Relevant surgical history in the last 3 months (e.g., but not limited to abdominal, thoracic, ocular or brain surgery).
  • History or evidence of lung resection, thoracotomy, known aneurysm and severe scoliosis.
  • Pregnancy.

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

T-326

Arm Description

Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.

Outcomes

Primary Outcome Measures

Peak inspiratory flow (L/min)

Secondary Outcome Measures

Inspiratory volumes (V in L)
Inspiratory time (t in s)

Full Information

First Posted
September 18, 2015
Last Updated
April 25, 2017
Sponsor
Bayer
Collaborators
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT02563197
Brief Title
Inhalation Flow Rate-study
Official Title
An Open, Multi-center Study to Measure Inhaled Flow Rates Generated by Non-CF Bronchiectasis Patients for the T-326 Inhaler
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
November 23, 2015 (Actual)
Primary Completion Date
February 17, 2016 (Actual)
Study Completion Date
April 29, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
Collaborators
Novartis

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.
Detailed Description
The aim of the study is to measure inspiratory profiles of patients with non-Cystic fibrosis bronchiectasis using the breath activated T-326 Inhaler. The following parameters will be derived from the inspiratory profiles: Peak Inspiratory Flow (PIF, in L/min) Inspiratory Volume (V, in L) Inspiratory Time (t, in s).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchiectasis
Keywords
Device study, Peak inspiratory flow rate, Non-cystic fibrosis bronchiectasis, T-326 Inhaler

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
T-326
Arm Type
Experimental
Arm Description
Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
Intervention Type
Device
Intervention Name(s)
T-326 Inhaler
Intervention Description
No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
Primary Outcome Measure Information:
Title
Peak inspiratory flow (L/min)
Time Frame
Visit 2 (1-14 days after screening visit 1)
Secondary Outcome Measure Information:
Title
Inspiratory volumes (V in L)
Time Frame
Visit 2 (1-14 days after screening visit 1)
Title
Inspiratory time (t in s)
Time Frame
Visit 2 (1-14 days after screening visit 1)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Established diagnosis of non-cystic fibrosis bronchiectasis, confirmed and documented by high resolution computed tomography (HRCT) or magnetic resonance tomography (MRT) Ability to reproducibly perform spirometry according to American Thoracic Society/European Respiratory Society criteria Clinically stable in the opinion of the investigator at the time of the study visit. Male and female patients ≥ 18 years of age. Exclusion Criteria: Pulmonary exacerbation (as judged by the investigator, based on the clinical condition of the subject and taking into account e.g., febrile infection of the lung, relevant decrease in Forced expiratory volume in the first second (FEV1) value, increased sputum production, sputum purulence, recent hospitalization) at study visit or within the preceding six (6) weeks. History of lung transplant. Recent significant hemoptysis (≥ 300 mL or requiring blood transfusion) in the preceding six (6) weeks before screening. Established diagnosis of bronchial asthma. Established diagnosis of cystic fibrosis. Proof of any relevant medical finding or disease in the last three (3) months which might interfere with participation in the study or patient safety (e.g. pneumothorax, uncontrolled hypertension, uncontrolled cardiac arrhythmia, myocardial infarction, cerebral vascular accident). A relevant disease that is considered to interfere with the study results is any disease that, except for the impairment of lung function, interferes with the patient's ability to inhale from the device. For example, COPD per se is usually not considered as a reason for patient exclusion, unless coughing or obliteration of the upper airways with sputum interferes with the patient's ability to inhale from the device. Relevant surgical history in the last 3 months (e.g., but not limited to abdominal, thoracic, ocular or brain surgery). History or evidence of lung resection, thoracotomy, known aneurysm and severe scoliosis. Pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
Facility Information:
City
Gauting
State/Province
Bayern
ZIP/Postal Code
82131
Country
Germany
City
Landsberg
State/Province
Bayern
ZIP/Postal Code
86899
Country
Germany
City
München
State/Province
Bayern
ZIP/Postal Code
80336
Country
Germany
City
München
State/Province
Bayern
ZIP/Postal Code
80539
Country
Germany
City
München
State/Province
Bayern
ZIP/Postal Code
81241
Country
Germany
City
Frankfurt
State/Province
Hessen
ZIP/Postal Code
60389
Country
Germany
City
Frankfurt
State/Province
Hessen
ZIP/Postal Code
60596
Country
Germany
City
Neu-Isenburg
State/Province
Hessen
ZIP/Postal Code
63263
Country
Germany
City
Hannover
State/Province
Niedersachsen
ZIP/Postal Code
30625
Country
Germany
City
Grosshansdorf
ZIP/Postal Code
22927
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
30848695
Citation
Stass H, Nagelschmitz J, Kappeler D, Sommerer K, Patzlaff A, Weimann B. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2019 Jun;32(3):156-163. doi: 10.1089/jamp.2018.1464. Epub 2019 Mar 8.
Results Reference
derived

Learn more about this trial

Inhalation Flow Rate-study

We'll reach out to this number within 24 hrs